$JOE

One Billionaire Fund Has Nearly 80% of Its Portfolio in a Single Stock

Fairholme Capital Management’s Fairholme fund reported in its Q1 2026 13F that about 79.7% of its portfolio is in The St. Joe Company (NYSE:JOE). The article says JOE grew 2025 net income 55.8% to $115.6M and revenue 27.4% to $513.2M. It also notes Fairholme sold about $25M of JOE in 14 transactions in mid-2026 while retaining 15.1M shares.

Original reporting
Published Jul 26, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 26, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
One Billionaire Fund Has Nearly 80% of Its Portfolio in a Single Stock — source image
Decision brief

The 30-second read

$JOENeutralLow
01

Why it matters

The trading relevance is mainly about how a high-conviction, concentrated holder is managing exposure (trimming while retaining a large stake), alongside a fundamentals snapshot (2025 growth, margins, and recurring revenue mix).

02

Market read

For traders, the key takeaway is sentiment and positioning around a concentrated holder in JOE, supported by a fundamentals recap rather than a new catalyst.

03

What to watch

The article cites DCF intrinsic value and forward P/E, but does not provide updated land cost assumptions, development timing risk, or sensitivity to housing demand and builder contract execution.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning based on reported 13F concentration and mid-2026 trimming disclosures

Background

Fairholme Capital Management is described as running an unusually concentrated position in The St. Joe Company, with the article referencing its Q1 2026 13F filing and mid-2026 share sales.

Company-level read

Ticker impact

$JOENeutralMedium confidence
Context

The article says Fairholme’s 13F shows ~79.7% of its portfolio in St. Joe (JOE) and details JOE’s 2025 results and 2026 trimming activity.

Expected impact

Near-term price impact is likely limited; any effect would come from investor sentiment around the fund trimming, not from new JOE fundamentals.

Evidence & confidence

The newest concrete facts are the reported concentration level and the fund’s sale transactions, plus cited operating metrics (2025 revenue, net income, margins). There is no new JOE guidance, contract award, or regulatory action disclosed.

Market effects

Highlights how land and homebuilding-adjacent developers can be valued on pricing power and recurring revenue mix, potentially influencing sentiment toward regional real estate developers.

Reinforces investor focus on Northwest Florida land and development pipelines as a durable growth market.

Limited; this is primarily a single-company, US regional real estate story.

Counterpoint

A large 13F concentration plus trimming into record highs can signal that the risk-reward has deteriorated even if fundamentals look strong, especially given lumpy closing timing and JV equity income volatility.

Key entities

  • The St. Joe Company

    Northwest Florida real estate developer; article cites 2025 revenue/net income growth, margin expansion, and a large land portfolio.

  • Fairholme Capital Management

    Berkowitz’s fund; article claims ~79.7% of its 13F portfolio is in JOE and details multiple sale transactions while retaining >15M shares.

  • D.R. Horton, Toll Brothers, PulteGroup

    Builders referenced as development partners and as validating demand via a homesite contract.

Related articles

$JOEMed

THE ST. JOE COMPANY REPORTS THIRD QUARTER AND FIRST NINE MONTHS OF 2026 RESULTS AND INCREASES QUARTERLY DIVIDEND BY 13% TO $0.18 PER SHARE

ST JOE Co (JOE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ THE ST. JOE COMPANY REPORTS THIRD QUARTER AND FIRST NINE MONTHS OF 2026 RESULTS AND INCREASES QUARTERLY DIVIDEND BY 13% TO $0.18 PER SHARE ​ Highlights for the third quarter of 2026 as compared to the third quarter of 2025. The comparability of period over period

$JOEMed

THE ST. JOE COMPANY REPORTS SECOND QUARTER AND FIRST HALF 2026 RESULTS AND DECLARES A QUARTERLY DIVIDEND OF $0.16 PER SHARE

ST JOE Co (JOE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ THE ST. JOE COMPANY REPORTS SECOND QUARTER AND FIRST HALF 2026 RESULTS AND DECLARES A QUARTERLY DIVIDEND OF $0.16 PER SHARE ​ Highlights for the second quarter of 2026 as compared to the second quarter of 2025: ​ · Quarterly net income increased by 37% to $40.5 m

$NEXTMed

NextDecade Corporation Q3 2026 Earnings Call Summary

NextDecade Corporation reported Q3 2026 progress, with Phase I construction ahead of schedule and first LNG production expected in Q2 2027. The company refinanced $7B in debt and plans to reach a final investment decision for Train 6 in H2 2027. Management expects strong returns and is maintaining a long position on 1,100 TBtu of uncontracted volumes to capitalize on market volatility.

$NIMed

NiSource Data Center Plan: $28B Capital, $7B Power [2026]

NiSource Inc. (NI) plans $28B capital investment from 2026-2030, with $7B allocated to data-center infrastructure. The company has secured long-term energy agreements with Alphabet and Amazon for data centers in Indiana, approved by regulators. NiSource aims to balance new customer needs with existing ratepayer protections.

$SNDRMed

Schneider to shift intermodal business to Norfolk Southern

Schneider, the third-largest domestic intermodal company, will shift its eastern freight to Norfolk Southern starting January 1, 2024. The move aims to expand market access, increase network flexibility, and strengthen Schneider's competitive position. Norfolk Southern expects the partnership to enhance rail's role in the domestic supply chain. Schneider previously partnered with CSX in the East and Union Pacific in the West.

$CVSMed

UK sues CVS Health for $41 million over alleged Rx contract breach

The University of Kentucky sued CVS Health, alleging the company withheld $41 million in revenue meant for the university under a federal pharmacy agreement. The lawsuit claims CVS charged full rates instead of discounted prices, keeping the savings. CVS denies wrongdoing, stating it remains focused on supporting under-served populations. The university seeks financial redress and to terminate the contract.